Welch Allyn, Inc.

Company overview. Welch Allyn, Inc. is an American medical device manufacturer founded in 1915 in Auburn, New York, and headquartered at 4341 State Street Road, Skaneateles Falls, New York. It was family-owned for a century before Hill-Rom Holdings acquired it in September 2015 for roughly $2.05 billion. Baxter International (NYSE: BAX) then acquired Hillrom in December 2021 for $10.5 billion, making Welch Allyn an indirect, wholly owned subsidiary of Baxter. It is not separately publicly traded and does not file its own 10-K. Crunchbase reports more than 2,750 employees historically, and local press cites roughly 1,000 at the Skaneateles Falls plant. Current headcount and revenue are not separately disclosed by Baxter.

Products / services. Welch Allyn is an operating company, not an NPE. Its core lines are physical-examination and diagnostic instruments — handheld ophthalmoscopes (the founding product), otoscopes, stethoscopes, blood-pressure cuffs and thermometry, audiology/hearing screening equipment — plus point-of-care vital signs and patient monitoring, diagnostic cardiology (ECG/Holter monitors, through Hillrom's Mortara and Bardy Diagnostics acquisitions), and miniature precision lamps. Welch Allyn products carry the Welch Allyn brand within Baxter's "Frontline Care" business, and the company has supplied patient monitoring systems to the U.S. armed forces under a five-year, $100M contract awarded in 2019.

Patent-litigation posture. The tracked data show one case, as plaintiff and none as defendant — consistent with an operating company enforcing its own portfolio, not a patent assertion entity. Welch Allyn's patents trace to its own ambulatory ECG monitor R&D (the Micropaq monitor). The suit was filed in the District of Delaware rather than a plaintiff-friendly venue like the Eastern District of Texas, reflecting that Delaware is defendant iRhythm's state of incorporation.

Notable case. Welch Allyn, Inc. v. iRhythm Technologies, Inc., No. 1:24-cv-00224-MN (D. Del., filed Feb. 20, 2024), accused iRhythm's Zio AT, Zio XT and next-generation Zio monitors of infringing several Welch Allyn ECG-monitor patents (including U.S. 8,214,007; 8,965,492; 9,155,484; 10,159,422; 8,630,699; 8,750,974). iRhythm filed IPR petitions (IPR2025-00363 and others) that the USPTO discretionarily declined to institute. Per iRhythm's SEC filings, the parties settled on July 31, 2026 under a Baxter Settlement Agreement. A related Baxter-unit suit, Bardy Diagnostics, Inc. v. iRhythm Technologies, Inc. (D. Del.), was filed in 2024.